AdvanCell’s Generator is a world-first alpha isotope generator which addresses the greatest unmet need in targeted alpha therapy – the reliable and scalable supply of isotope. The manufacture of clinical doses of a high-value isotope Alpha 212® (Lead-212) for use in targeted radionuclides therapy is a game-changer for prostate and several other cancer treatments. Enabling scalable local isotope production capability, the Generator will fast track the delivery of cutting-edge cancer treatments to patients.